Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × Hordeolum × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 697 Breast Neoplasms 645 Carcinoma, Non-Small-Cell Lung 638 Neoplasm Metastasis 299 Colorectal Neoplasms 294 Prostatic Neoplasms 291 Multiple Myeloma 256 Melanoma 255 Leukemia, Myeloid, Acute 206 Ovarian Neoplasms 200 Recurrence 199 Lymphoma, Non-Hodgkin 180 Lung Neoplasms 179 Carcinoma, Renal Cell 177 Lymphoma 162 Lymphoma, Follicular 143 Pancreatic Neoplasms 141 Leukemia, Lymphocytic, Chronic, B-Cell 133 Carcinoma, Hepatocellular 128 Leukemia 117 Stomach Neoplasms 115 Lymphoma, Large B-Cell, Diffuse 108 Head and Neck Neoplasms 105 Parkinson Disease 4, Autosomal Dominant Lewy Body 102 Urinary Bladder Neoplasms 96 Carcinoma 95 Precursor Cell Lymphoblastic Leukemia-Lymphoma 88 Squamous Cell Carcinoma of Head and Neck 86 Small Cell Lung Carcinoma 86 Glioblastoma 85

Interventions

Loteprednol Etabonate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00420628 2011-10-07

Pediatric Zylet Safety and Efficacy Study

Bausch & Lomb Incorporated

Phase 4 Completed

108 enrolled 11 charts

Hordeolum, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡